Teng Xu

机构：Shandong University, Second Hospital of Shandong University

发表论文 15 篇 · 总被引 90 次 · h-index 5

代表论文

• The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma (2022 · Journal of Oncology · 被引 26)
• Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL (2022 · Blood Advances · 被引 19)
• CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results (2023 · Frontiers in Oncology · 被引 13)
• Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study (2024 · Annals of Hematology · 被引 12)
• Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma (2022 · Bone Marrow Transplantation · 被引 7)
• CD7 CART Therapy Bridging Allo-HSCT Remarkably Improves Long-Term DFS in Refractory/Relapsed T-ALL/LBL (2024 · Transplantation and Cellular Therapy · 被引 5)